Deutsche Bank
NBIX icon

Deutsche Bank’s Neurocrine Biosciences NBIX Stock Holding History

Deutsche Bank’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-200
Closed -$4K – 5681
2014
Q4 		$4K Buy
+200
New +$3.79K ﹤0.01% 5923

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Deutsche Bank's NBIX Position: Q1 2026 in Review

Deutsche Bank reduced its Neurocrine Biosciences (NBIX) stake by 0.71% in Q1 2026, selling an estimated $345K and leaving 365,345 shares worth $48.1M. The position accounts for 0.02% of the portfolio, ranked #635.

Deutsche Bank first reported a position in NBIX in Q2 2013 and has held it in 52 quarters since. The position peaked at $114M in Q3 2018. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • Deutsche Bank held 365,345 shares of Neurocrine Biosciences worth $48.1M as of Q1 2026.
  • Deutsche Bank sold 2,599 Neurocrine Biosciences shares in Q1 2026, an estimated $345K.
  • Neurocrine Biosciences made up 0.02% of Deutsche Bank's portfolio in Q1 2026, its #635 holding.
  • Deutsche Bank first reported a position in Neurocrine Biosciences in Q2 2013 and has held it in 52 quarters since.
  • Deutsche Bank's Neurocrine Biosciences position peaked at $114M in Q3 2018.
  • 694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Deutsche Bank's 13F filing for Q1 2026, filed 6 May 2026.